Device/Drug Update
CamAPS Liberty: Advancing Fully Closed-Loop Insulin Delivery for Type 1 Diabetes
mylife Diabetes Care and CamDiab have introduced CamAPS Liberty, a fully closed-loop feature within the CamAPS FX app, integrated into the mylife Loop automated insulin delivery (AID) system. Designed to simplify type 1 diabetes management, this innovation aims to reduce the need for routine manual interventions associated with insulin delivery. Unlike conventional hybrid closed-loop systems, which generally require users to announce meals and administer or confirm mealtime insulin boluses, CamAPS Liberty is designed to operate without carbohydrate counting or manual pre-meal insulin boluses. Powered by a more proactive version of the CamAPS algorithm, the feature anticipates and responds to changes in glucose levels while operating within established safety boundaries. The mylife Loop system combines the YpsoPump insulin pump, the CamAPS FX smartphone application and compatible continuous glucose monitoring (CGM) systems, integrating glucose monitoring and algorithm-driven insulin delivery into a coordinated system. By reducing the number of diabetes-related decisions required throughout the day, the technology aims to make insulin therapy more convenient and flexible for people living with type 1 diabetes.
Beyond glycaemic control, CamAPS Liberty highlights the growing emphasis on reducing the cognitive and emotional demands of living with diabetes. Minimising the need for carbohydrate calculations and manual mealtime insulin boluses may help ease the daily workload of diabetes management and support greater flexibility in everyday activities. However, individual glucose responses and insulin requirements vary, and automated insulin delivery does not eliminate the possibility of hypoglycaemia, hyperglycaemia or other diabetes-related complications. Users must continue to understand system alerts, recognise potential safety concerns and maintain appropriate clinical follow-up. The developers describe CamAPS Liberty as an important milestone in automated insulin delivery, reflecting the broader movement towards technologies that aim to simplify treatment while supporting quality of life.
Foundayo (Orforglipron): A Once-Daily Oral GLP-1 Receptor Agonist for Weight Management
Foundayo, developed by Eli Lilly, is an oral medication containing orforglipron, a non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike injectable GLP-1-based therapies, it is administered as a once-daily tablet and is designed to support weight reduction alongside a reduced-calorie diet and increased physical activity. By activating GLP-1 receptors, orforglipron helps regulate appetite, increase feelings of fullness and reduce food intake. It also has glucose-lowering effects in people with type 2 diabetes. An important practical feature is that the tablet can be taken at any time of day, with or without food, without specific food-related dosing restrictions. In the United States, the Food and Drug Administration (FDA) approved Foundayo for chronic weight management in eligible adults in April 2026. The United Kingdom subsequently authorised it in August 2026 for weight management and weight maintenance in eligible adults, as well as for improving glycaemic control in people with inadequately controlled type 2 diabetes.
The efficacy of orforglipron was evaluated in the phase 3 ATTAIN-1 trial, which included more than 3,000 adults with obesity or overweight and without diabetes. At the highest studied dose, participants taking orforglipron lost an average of 12.4% of their body weight over 72 weeks, compared with approximately 0.9% in the placebo group, alongside lifestyle interventions. Improvements were also observed in several cardiometabolic risk markers, including blood pressure, triglycerides and non-HDL cholesterol. Treatment begins at a low dose and is increased gradually, based on tolerability and clinical response, to reduce the likelihood of gastrointestinal adverse effects. Common adverse effects include nausea, diarrhoea, constipation and vomiting. Important precautions include the risk of dehydration-related kidney problems, pancreatitis and other serious adverse reactions. The medicine is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 under the US prescribing information. Although the oral formulation offers an alternative to injections, treatment should be individualised and monitored by a qualified healthcare professional.
Although orforglipron represents a promising development in oral obesity treatment, Foundayo is not yet available or launched in India. Its potential use in the country will depend on regulatory approval and commercial availability. Until then, patients should avoid unapproved sources and consult qualified healthcare professionals for evidence-based obesity and diabetes management.